United States Rapid Adenovirus Testing Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The "Global Rapid Adenovirus Testing Market" is predicted to reach at a high CAGR during the forecast period (2024-2031)

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/rapid-adenovirus-testing-market?sb

Key Development:

Rapid Adenovirus Testing: Recent Developments
✅ In April 2025, Orient Gene received IVDR certification for its COVID-19/Flu A&B/RSV/Adenovirus Antigen Combo Rapid Test Cassette. The approval enhances clinical reliability for multiplex respiratory testing. It enables 15-minute adenovirus detection using a single swab.

✅ In March 2025, Orient Gene confirmed expanded commercial deployment plans for its newly IVDR-certified multiplex adenovirus test. The rollout focuses on European and global point-of-care markets. It strengthens access to rapid adenovirus screening in decentralized settings.

✅ In February 2025, ProGnosis Biotech highlighted continued clinical usage of its Adenovirus Rapid Test across hospitals and labs. The lateral-flow test delivers ~15-minute results with high sensitivity and specificity. It supports fast detection of adenoviral infections, especially in pediatric cases.

✅ In January 2025, diagnostics analysts emphasized rising adoption of rapid adenovirus antigen assays driven by outbreaks and higher testing needs. Manufacturers reported scaling production of POC adenovirus kits. The trend reflects growing demand for fast, low-cost viral screening tools.

Key Players:

=> Biopanda Reagents Ltd, CTK Biotech Inc, Creative Diagnostics, Biomérieux India Private Limited, Accuquik, SA Scientific, F. Hoffmann-La Roche Ltd, Diasorin S.P.A, Bio-Rad Laboratories Inc., QIAGEN, Intec Products Inc.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=rapid-adenovirus-testing-market

Key Segments:

By Assay
Lateral flow immunochromatographic assays lead with 45% share, driven by low cost, speed and broad use in decentralized point-of-care settings for infectious disease screening. Immunogold assays account for 25%, supported by improved sensitivity for targeted antigen/antibody detection in clinical and research workflows. PCR-enzyme hybridization assays hold 30%, fueled by laboratory adoption for confirmatory molecular testing due to high sensitivity and specificity.

By Diagnosis
Polymerase Chain Reaction (PCR) dominates with 40% share as the gold standard for pathogen detection and high-accuracy molecular diagnostics. Antigen detection holds 25%, reflecting demand for rapid screening and outbreak response. Virus isolation represents 8%, used mainly in specialized virology labs and research. Monoclonal antibody-based methods account for 7%, supporting highly specific assays and therapeutic development. Liposome-based assays and flow cytometry together contribute 10%, applied in advanced diagnostics and immunophenotyping. Chromatography and gel-microdroplet techniques make up the remaining 10%, serving niche analytical and high-throughput research needs.

By End-User
Hospitals lead with 50% share, driven by inpatient testing, emergency diagnostics, and integrated lab services for rapid clinical decisions. Diagnostic laboratories account for 35%, supported by high-throughput PCR workflows and centralized confirmatory testing. Clinics represent 15%, reflecting reliance on point-of-care lateral flow and rapid antigen testing for outpatient screening.

By Region
North America - 35% Share. Advanced lab infrastructure, high molecular testing capacity, and significant R&D investment drive demand.
Europe - 25% Share. Strong centralized labs, public-health testing programs, and broad adoption of PCR and rapid tests.
Asia Pacific - 25% Share. Large public-health programs, expanding molecular lab networks, and wide use of point-of-care assays.
Latin America - 7% Share. Growing diagnostic capacity and expansion of rapid testing and lab networks.
Middle East & Africa - 8% Share. Increasing investment in diagnostics, surveillance programs, and point-of-care adoption.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/rapid-adenovirus-testing-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.